Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Clinical Study of the Efficacy and Safety of BCD-201 (JSC BIOCAD) and Keytruda® in Patients With Unresectable or Metastatic Melanoma

NCT05986331 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT05986331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05986331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Clinical Study of the Efficacy and Safety of BCD-201 (JSC BIOCAD) and Keytruda® in Patients With Unresectable or Metastatic Melanoma
Lead sponsor
Biocad
Phase
Phase 3
Overall status
Unknown status
Start date
July 18, 2022
Completion date
December 31, 2024
Enrollment
366 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)